View specs Tirzepatide
dual GIP / GLP-1 agonist

Built for people who have other things to think about.
One compound, two formats — a lyophilized vial and a pre-filled pen, each with the documentation behind it.
One compound. Two formats. A clearer path to understanding Tirzepatide, the documentation behind it, and our proposed research access program.
Explore research accessThe same dual GIP / GLP-1 receptor agonist, presented as a vial or pen.
View specs dual GIP / GLP-1 agonist
View specs dual GIP / GLP-1 agonist · pre-filled pen
Pharmaceutical compound presentations. Final specifications, regulatory status and availability must be confirmed with the team.
Product information, batch documentation and professional review each have a different role. We bring the questions together, without replacing a clinician’s judgement.


Our proposed research partnerships focus on recording relevant information, reviewing progress and keeping participation informed.
Program details are proposed. Participation and outcomes are not guaranteed.
An intake starts the conversation. These are the areas to discuss—not an automatic eligibility decision.
Start with what you want to understand and why you are exploring the program.
Share relevant conditions and medications for an informed professional review.
Our stated service area covers South and Centro-Oeste Brazil.
Understand the proposed check-ins and data consent before deciding to take part.
Know the format. Read the documentation. Ask the right questions. Our team can help you navigate product information and the proposed research program.
Talk to our team